

- **Name:** Sung Hee Lim
  - **Current Position & Affiliation:** Associate Professor & Samsung Medical Center
  - **Country:** Korea
- 

**• Educational Background:**

- Got Bachelor of Medicine, majored in medicine at Yonsei University, College of Medicine, Seoul, Korea (March 2003 ~ February 2009)
- Got Master of Medicine, majored in molecular oncology at Sungkyunkwan University School of Medicine, Seoul, Korea (March 2013 ~ February 2015)
- Got Doctor of Medicine, majored in molecular oncology at Sungkyunkwan University School of Medicine, Seoul, Korea (March 2015 ~ February 2020)

**• Professional Experience:**

- Mar 2024 – Current: Associate Professor, Division of Hematology-Oncology Department of Internal medicine, Samsung Medical Center
- Mar 2023 – Current: Assistant Professor, Division of Hematology-Oncology Department of Internal medicine, Samsung Medical Center
- Mar 2017 – Feb 2023: Assistant Professor, Division of Oncology-Hematology Department of Internal medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
- Mar 2016 – Feb 2017: Clinical Fellowship, Division of Hematology-Oncology, Department of Medicine, Dongtan Sacred Heart Hospital, Hallym University of College of Medicine, Hwaseong, Korea
- Mar 2014 – Feb 2016: Clinical Fellowship, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Mar 2010 – Feb 2014: Residency in Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Mar 2009 – Feb 2010: Internship, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

**• Main Scientific Publications:**

- Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial  
Sung Hee Lim, Minae An, Hyuk Lee, You Jeong Heo, Byung-Hoon Min, Arnav

Mehta, Samuel Wright, Kyoung-Mee Kim, Seung Tae Kim, Samuel J. Klempner, and Jeeyun Lee

Clinical Cancer Research 2025 March

- The safety and efficacy outcomes of Minnelide given alone or in combination with paclitaxel in advanced gastric cancer: A phase I trial.

Lim SH, Saluja A, Vickers S, Hong JY, Kim ST, Lavana S, Pandey S, Gupta VK, Velagapudi MR, Lee J.

Cancer Lett. 2024 Aug 10;597:217041. doi: 10.1016/j.canlet.2024.217041. Epub 2024 Jun 10.

- The Impact of Pembrolizumab as a Salvage Therapy Based on HER2 Expression in Advanced Gastric Cancer.

Lim SH, Kim MJ, Lee J, Lim HY, Kang WK, Kim ST.

Cancers (Basel). 2024 Aug 26;16(17):2969